P737 SPOSIB SB2: A Sicilian prospective observational study of patients with inflammatory bowel disease treated with infliximab Biosimilar SB2 (Flixabi®): interim analysis
2019 ◽
Vol 13
(Supplement_1)
◽
pp. S490-S490
2018 ◽
Vol 50
(3)
◽
pp. 240-246
◽
Keyword(s):
2013 ◽
Vol 7
(12)
◽
pp. e692-e697
◽